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AB1114 PATIENT'S SELF-MONITORING OF DISEASE ACTIVITY OF RHEUMATIC DISEASES VIA WEBAPP -STUDY DESIGN, PATIENT'S PERSPECTIVE AND RECRUITMENT IN THE FIRST 11 MONTHS OF THE SWISS MULTICENTRE, LONGITUDINAL COMPASS II STUDY
Objectives: The objectives of this abstract are to describe the set-up and the recruitment of the COmPASS II study in the first 11 months.
Methods:
The COmPASS II App questionnaire consists of the RAPID3 score, a validated, commonly used PRO to self-assess disease activity. Additionally, patients are asked about their therapy compliance and cortisone dose. At inclusion, interested patients with RA, axSpA and PsA are electronically randomized into 3 study arms (Figure 1) . In arm 1 patients and rheumatologist are displayed the self-assessed disease activity over time, the patient directly via the App and the rheumatologist via the SCQM registry. In arm 2 only the patients are displayed their disease activity chart and in study arm 3 neither sees the recorded data. Patients are encouraged to fill in the App weekly. Results: The COmPASS II App went online on the 15/02/2016. In the first 11 months of COmPASS II, 272 patients were enrolled by their rheumatologist. 64% of patients used the WebApp (32% in arm 1, 38% in arm 2 and 30% in arm 3); 82% of patients filled in the questionnaires for longer than a months, the longest follow-up was 11 months. On average patients use the App every 2 weeks. Patients found the App easy to use "The COmPASS II WebApp is so easy to use. It doesn't even take me 2 min." and received feedback included "Now my rheumatologist sees how I was since the last appointment instead of me trying to remember how I was half a year ago.".
Conclusions:
The COmPASS II study will validate the utility of app-based patients' self-assessments in enhancing disease control in a treat to target approach and deliver numerous additional scientific data. 
